Professor Naveed Sattar was a co-author on the Emperor Preserved trial, published in NEJM
Professor Naveed Sattar was a co-author on the Emperor Preserved trial, published in NEJM https://www.nejm.org/doi/10.1056/NEJMoa2107038, demonstrating benefit of the SGLT2 inhibitor, Empagliflozin, for reducing the primary end-point of a composite of cardiovascular death or hospitalization for heart failure. Risk was reduced by 21%, (95% CI 10 to 31%), as in figure below. This trial is important as previous large-scale trials of drug interventions in patients with heart failure and a preserved ejection fraction have failed to demonstrate unequivocal benefits of treatment on the primary heart failure outcome. The results are encouraging for the DELIVER trial, testing the effects of Dapagliflozin in this same population and co-led by Professors Scott Solomon, Brigham and Women's Hospital, Boston and Professor John McMurray, Glasgow, due out next year.
Naveed also contributed to the new ESC CV prevention guidelines as committee member https://academic.oup.com/eurheartj/article/42/34/3227/6358713, a summary of the best evidence of risk factors for cardiovascular disease and proven preventative therapies. The paper also includes some novel ways to identify people deserving of more intensive interventions, including use of lifetime risk and other novel metrics. Worth a read!
First published: 1 October 2021